Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01780506 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

A Phase 3 study of HIV Infections and HIV, sponsored by Gilead Sciences.

Completed
Registry status
Phase 3
Development phase
872
Enrollment target
20
Study locations

NCT01780506: Completed Phase 3 study of HIV Infections and HIV, sponsored by Gilead Sciences.

NCT01780506 is a Phase 3 study of HIV Infections and HIV that has completed, run by Gilead Sciences. The registered enrollment target is 872 participants, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (96% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01780506, a Phase 3 study of HIV Infections and HIV, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 3
Development phase
872 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.

Primary Outcome

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Conditions Studied

HIV Infections HIV

Interventions

  • DRUG E/C/F/TAF
  • DRUG E/C/F/TDF
  • DRUG E/C/F/TDF Placebo
  • DRUG E/C/F/TAF Placebo

Study Locations (20)

California

  • Kaiser Permanente Los Angeles - Los Angeles
  • University of California, Los Angeles - Los Angeles
  • Peter J. Ruane, MD, Inc. - Los Angeles
  • Anthony Mills MD Inc - Los Angeles
  • East Bay AIDS Center - Oakland
  • Kaiser Permanente - Sacramento - Sacramento
  • La Playa Medical Group and Clinical Research - San Diego
  • University of California, San Diego - San Diego
  • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance

Florida

  • Gary Richmond, MD, PA, Inc. - Fort Lauderdale
  • Midway Immunology & Research Center, LLC - Ft. Pierce
  • The Kinder Medical Group - Miami
  • AIDS Healthcare Foundation - Miami Beach

District of Columbia

  • Dupont Circle Physicians Group, P.C. - Washington D.C.
  • Whitman Walker Clinic - Washington D.C.
  • Capital Medical Associates, P.C. - Washington D.C.

Alabama

  • The University of Alabama at Birmingham - Birmingham

Arizona

  • Spectrum Medical Group - Phoenix

Colorado

  • Apex Research, LLC - Denver

Connecticut

  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 872 participants
Start Date 2012-12-26
Est. Completion 2017-09-06
Phase Phase 3
Gilead Sciences

504 total trials

What the finished NCT01780506 record still lists

NCT01780506 is an interventional study that assigns participants to a tested intervention. The registered 872 participants enrollment target is mid-sized for trials with a published cap, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (96% higher).

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which E/C/F/TAF is the first listed.

NCT01780506 names 20 study sites across 7 states, led by California, Florida, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT01780506 about?

NCT01780506 is a clinical study titled "Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults". The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatme...

What is the current status of trial NCT01780506?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 872 participants. The study started on 2012-12-26. Estimated completion is 2017-09-06.

What conditions does trial NCT01780506 study?

This clinical trial studies the following conditions: HIV Infections, HIV.

What interventions are being tested in trial NCT01780506?

The interventions under investigation include: E/C/F/TAF (DRUG), E/C/F/TDF (DRUG), E/C/F/TDF Placebo (DRUG), E/C/F/TAF Placebo (DRUG).

Who is sponsoring clinical trial NCT01780506?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01780506 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01780506's enrollment target sits among peer trials

872 35th of 542 higher than 508 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04097145 · 870 participants · NA

    Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • NCT06822790 · 869 participants · Phase 3

    Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

  • NCT06077760 · 868 participants · Phase 3

    A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

  • NCT07076199 · 877 participants · Phase 3

    A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT01780506, the US trial registry maintained by the National Library of Medicine. NCT01780506 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.